Dr. Cory Brooks, a chemistry and biochemistry professor at Fresno State and the newly named Editor-in-Chief of the Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, said his appointment to head the respected publication is a recognition of Fresno State’s growing clout as a research institution. 

“The College of Science and Mathematics has recruited a new generation of scientists who are engaging students in research projects, securing grant funding, and publishing in peer-reviewed journals more than ever,” Dr. Brooks said. 

The Monoclonal Antibodies in Immunodiagnosis and Immunotherapy is a peer-reviewed journal that focuses on enhancing knowledge of biology and immunology to highlight the use of antibodies in diagnostics and treatments.

Fresno State is classified as an R2 status institution, denoting the university is engaged in high research activities. 

According to the journal’s announcement, Dr. Brooks is recognized for his expertise in structural biology and antibody-antigen interactions, particularly in nanobodies and cancer immunotherapy. He has a strong background in protein engineering and a notable publication record, having co-authored more than 40 papers. 

“Academics place a high value on recognition for our scholarly contributions, which often go unnoticed. For

this reason, it was a personal honor to have been recognized as an expert in my field of study,” Dr. Brooks said. 

Click here to read Dr. Brook’s appointment announcement published in the Monoclonal Antibodies in Immunodiagnosis and Immunotherapy journal.